These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2874411)

  • 1. Mechanism of action of adjuvant chemotherapy in early breast cancer.
    Padmanabhan N; Howell A; Rubens RD
    Lancet; 1986 Aug; 2(8504):411-4. PubMed ID: 2874411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour.
    Beex LV; Mackenzie MA; Raemaekers JM; Smals AG; Benraad TJ; Kloppenborg PW
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):719-21. PubMed ID: 3383972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
    Howell A; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Rubens RD; Hayward JL; Bulbrook RD; Fentiman IS
    Lancet; 1984 Aug; 2(8398):307-11. PubMed ID: 6146861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer.
    Brincker H; Mouridsen HT; Andersen KW
    Breast Cancer Res Treat; 1983; 3(1):91-5. PubMed ID: 6347278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
    Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
    J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial.
    Richards MA; O'Reilly SM; Howell A; George WD; Fentiman IS; Chaudary MA; Crowther D; Rubens RD
    J Clin Oncol; 1990 Dec; 8(12):2032-9. PubMed ID: 2230895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
    Bonadonna G; Rossi A; Tancini G; Bajetta E; Marchini S; Brambilla C; Tesoro Tess JD; Valagussa P; Banfi A; Veronesi U
    Cancer Treat Rep; 1981; 65 Suppl 1():61-5. PubMed ID: 7034930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
    Partridge A; Gelber S; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Winer E
    Eur J Cancer; 2007 Jul; 43(11):1646-53. PubMed ID: 17512721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London.
    Lancet; 1993 May; 341(8856):1293-8. PubMed ID: 8098446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
    Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
    Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
    [No Abstract]   [Full Text] [Related]  

  • 16. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
    Aebi S; Gelber S; Castiglione-Gertsch M; Gelber RD; Collins J; Thürlimann B; Rudenstam CM; Lindtner J; Crivellari D; Cortes-Funes H; Simoncini E; Werner ID; Coates AS; Goldhirsch A
    Lancet; 2000 May; 355(9218):1869-74. PubMed ID: 10866443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients.
    Poikonen P; Saarto T; Elomaa I; Joensuu H; Blomqvist C
    Eur J Cancer; 2000 Jan; 36(1):43-8. PubMed ID: 10741293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy (CMF) for stage III breast cancer: a randomized trial.
    Derman DP; Browde S; Kessel IL; De Moor NG; Lange M; Dansey R; Seymour L; Bezwoda WR
    Int J Radiat Oncol Biol Phys; 1989 Aug; 17(2):257-61. PubMed ID: 2666363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.